Oncology: GSK Acquires U.S. Biotech IDRx

The British pharmaceutical giant GSK has announced the acquisition of the Boston-based biopharmaceutical company IDRx for $1.15 billion. This strategic acquisition is a key part of GSK’s broader plan to expand its portfolio through external investments. The deal will see GSK pay an upfront amount of $1 billion, with an additional potential payment of $150 million contingent on the achievement of specific milestones related to the company’s product pipeline.

The acquisition includes IDRx’s leading molecule, IDRX-42, which is used in the treatment of gastrointestinal stromal tumors (GIST), a rare and difficult-to-treat cancer. This acquisition enhances GSK’s oncology portfolio, bringing valuable new assets into the fold.

This acquisition follows a series of similar moves by GSK, which has been actively pursuing growth through acquisitions. The British pharmaceutical company had previously acquired Bellus Health for $2 billion and Sierra Oncology for $1.9 billion. GSK’s executives have expressed their intention to continue seeking out strategic opportunities, stating, “We hope to identify more opportunities like IDRx and pursue similar acquisitions in the future, enhancing our capabilities and broadening our oncology offerings.”

https://www.sanita33.it/mercato/4660/oncologia-gsk-acquista-la-biotech-usa-idrx.html